Intel Prices $20 Billion Common Stock Offering at $95 per Share

Intel announced the upsizing and pricing of a $20 billion common stock offering on August 10, 2026, consisting of 210.5 million shares priced at $95 each (WSJ). The offering was expected to close on August 12, 2026, subject to customary closing conditions (Intel Newsroom). The offering size could increase to well over $20 billion if the over-allotment option is exercised (The Business Times).

The capital raise follows an April 8, 2026 equity transaction and an April 30, 2026 issuance of $1 billion in aggregate principal amount of 4.650% notes (SEC filing). As of April 17, 2026, Intel had 5,026 million shares of common stock outstanding (SEC filing). The 210.5 million shares in this offering would represent approximately 4.2% dilution against that base — a figure worth noting before the additional warrants and SoftBank investment are layered in.

The $20 billion raise is the latest and largest component in a multi-layered recapitalization that spans both equity and government capital. SoftBank Group and Intel signed a $2 billion investment agreement under which SoftBank pays $23 per share for Intel common stock (Intel Newsroom). The $23 strike is roughly 76% below the $95 public offering price, reflecting the structured nature of that private placement and its likely lockup or vesting conditions — though the specific terms beyond price are not detailed in the verified materials.

Separately, Intel and the Trump Administration reached an agreement under which the government will receive a five-year warrant at $20 per share for an additional five percent of Intel common shares (Intel Newsroom, published August 22, 2025). That warrant structure gives the federal government embedded upside exposure at a strike far below the current offering price, functioning as both a capital injection mechanism and a contingent equity stake.

The government involvement builds on prior CHIPS Act funding. Intel and the Biden administration announced up to $8.5 billion in direct funding under the CHIPS Act on March 20, 2024 (Intel Newsroom). The Trump-era warrant agreement layered additional federal capital exposure on top of that earlier grant.

Intel's revenue and spending trajectory provides context for why the company is tapping markets so aggressively. Intel Products revenue was $15.1 billion in Q2 2026 and $27.9 billion year-to-date (SEC filing). R&D expenses have been contracting: $13.8 billion in 2025, down from $16.5 billion in 2024 and $16.0 billion in 2023 (SEC filing). On July 24, 2026, Intel forecast third-quarter revenue above Wall Street expectations and raised its full-year capital expenditure estimate to $20 billion (Reuters).

The raised capex guidance and the $20 billion equity raise are sized to each other almost exactly. That is not coincidental. Intel is funding a significant portion of its forward capital investment program with fresh equity rather than debt — a decision that trades dilution for balance sheet capacity. The April $1 billion note issuance at 4.650% was modest by comparison, suggesting the debt markets were not the primary intended funding channel for the larger program.

For existing shareholders, the dilution math is straightforward but layered. The 210.5 million new shares at $95 add roughly $20 billion in equity capital. The SoftBank placement at $23 per share adds further shares at a steep discount. The government's five-year warrant for five percent of common shares at a $20 strike creates additional contingent dilution if exercised. Taken together, the total share count expansion — actual and potential — is material relative to the 5,026 million shares outstanding as of April.

The broader context here is a company simultaneously cutting R&D, raising capex, and issuing equity at scale. Intel's R&D fell from $16.5 billion in 2024 to $13.8 billion in 2025, a decline of roughly 16%. Over the same period, the company is committing to $20 billion in annual capital expenditure. The implication is a reallocation from research toward physical capacity build-out — fab construction and manufacturing infrastructure — funded in part by equity issuance rather than operating cash flow. Whether that bet pays off depends on whether the capacity comes online fast enough to generate returns before the dilution and capex drag on earnings becomes a persistent overhang.

The offering's timing, coming after a Q2 revenue beat and above-consensus Q3 guidance, suggests Intel is capitalizing on improved market sentiment to price the raise at a favorable level. The $95 per share price is a stark premium to the $23 SoftBank strike and the $20 government warrant strike, reflecting the difference between a public market raise and structured private or government investments with different risk-return profiles.

The over-allotment option, if exercised, would push total proceeds beyond $20 billion and increase dilution proportionally. The closing is contingent on customary conditions, and the offering is structured as a standard common stock sale rather than a convertible or preferred instrument.